AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Pixium Vision

Report Publication Announcement Jan 23, 2017

1599_iss_2017-01-23_b44ae612-3fe6-4bd4-81f7-76482b8f4bbd.pdf

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Pixium Vision's 2017 financial calendar

Paris, January 23rd , 2017 – Pixium Vision (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announces its 2017 financial calendar*:

  • 21st February, 2017 Full year 2016 financial results
  • 25 th April, 2017 – Sales for the first quarter of 2017
  • 16th May, 2017 Annual General Shareholders' Meeting
  • 27th July, 2017 Half year 2017 financial results
  • 26th October, 2017 Sales for the first nine month of 2017

* This financial calendar is for indicative purposes only. Pixium Vision may change the above dates if deemed necessary.

ABOUT PIXIUM VISION

Pixium Vision's Mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention as well as a rehabilitation period.

The company is developing two bionic retinal implant systems. IRIS®II, the company first bionic system, obtained CE mark in July 2016. In parallel, Pixium Vision has recently completed the pre-clinical study phases for PRIMA, a sub-retinal miniaturized wireless photovoltaic implant platform, and is planning to initiate first-inhuman trials.

Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including the Institut de la Vision in Paris, the Hansen Experimental Physics Laboratory at Stanford University, and Moorfields Eye Hospital in London. The company is EN ISO 13485 certified.

For more information, please visit: www.pixium-vision.com; And follow us on: @PixiumVision; www.facebook.com/pixiumvision www.linkedin.com/company/pixium-vision

Pixium Vision is listed on Euronext (Compartiment C) in Paris. ISIN: FR0011950641; Mnemo: PIX IRIS® is a trademark of Pixium-Vision SA Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Contacts

Pixium Vision Khalid Ishaque, CEO [email protected] +33 1 76 21 47 68

MediaRelations : Newcap Media Annie-Florence Loyer [email protected] +33 1 44 71 00 12 / +33 6 88 20 35 59

Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise. For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).

Talk to a Data Expert

Have a question? We'll get back to you promptly.